Clinical Trials on Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
Total 9 results
-
Zhejiang Cancer HospitalNot yet recruitingGastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and SurgeryChina
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical CarcinomaChina
-
Peking Union Medical College HospitalRecruitingAnlotinib | Anti-PD-1 Antibody | Advanced Pancreatic CancerChina
-
Lei LiRecruitingChemotherapy | Recurrent Cervical Carcinoma | Immune Checkpoint Inhibitors | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma | Albumin-bound PaclitaxelChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingChemotherapy Effect | Lung Cancer Stage IV | PD-1 Antibody | Lung Cancer Squamous CellChina
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Chest HospitalUnknownChemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
-
Shanghai Jiao Tong University Affiliated Sixth...RecruitingCervical Cancer | Radiotherapy | Neoadjuvant Chemotherapy | PD-1 AntibodyChina
-
Lei LiUnknownCamrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine CarcinomasChemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 AntibodyChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingOvarian Cancer | Neoadjuvant Chemotherapy | Anti-PD-1 | Neoadjuvant ImmunotherapyChina